Referências

1. Johnson PWM, Sydes MR, Hancock BW, Et al., Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519), J Clin Oncol, 28, 20, pp. 3352-3359, (2010)
2. Laskar S, Gupta T, Vimal S, Et al., Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?, J Clin Oncol, 22, 1, pp. 62-68, (2004)
3. Aleman BMP, Raemaekers JMM, Tomisic R, Et al., European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma, Int J Radiat Oncol Biol Phys, 67, 1, pp. 19-30, (2007)
4. Zinzani PL, Fanti S, Battista G, Et al., Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients, Br J Cancer, 91, 5, pp. 850-854, (2004)
5. Terasawa T, Nihashi T, Hotta T, Et al., 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: a systematic review, J Nucl Med, 49, 1, pp. 13-21, (2008)
6. Gallamini A, Rossi A, Patti C, Et al., Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial, J Clin Oncol, 38, 33, pp. 3905-3913, (2020)
7. Ricardi U, Levis M, Evangelista A, Et al., Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial, Blood Adv, 5, 21, pp. 4504-4514, (2021)
8. Qi S, Milgrom S, Dabaja B, Et al., Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease, Blood Adv, 4, 9, pp. 2064-2072, (2020)
9. Benveniste MF, Gomez D, Carter BW, Et al., Radiation Effects in the Mediastinum and Surroundings: Imaging Findings and Complications, Semin Ultrasound CT MR, 37, 3, pp. 268-280, (2016)
10. Cheson BD, Fisher RI, Barrington SF, Et al., Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, Ger
11. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 27, pp. 3059-3068, (2014)
12. Lee C, Bloomfield C, Goldman A, Et al., Prognostic significance of mediastinal involvement in Hodgkin’s disease treated with curative radiotherapy, Cancer, 46, 11, pp. 2403-2409, (1980)
13. Biggi A, Gallamini A, Chauvie S, Et al., International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers, J Nucl Med, 54, 5, pp. 683-690, (2013)
14. Harris PA, Taylor R, Thielke R, Et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, 42, 2, pp. 377-381, (2009)
15. Aleman BMP, Raemaekers JMM, Tirelli U, Et al., European Organization for Research and Treatment of Cancer Lymphoma Group. Involved-field radiotherapy for advanced Hodgkin’s lymphoma, N Engl J Med, 348, 24, pp. 2396-2406, (2003)
16. Swerdlow SH, Campo E, Pileri SA, Et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 20, pp. 2375-2390, (2016)
17. Dunleavy K., Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies, Hematology Am Soc Hematol Educ Program, 2017, 1, pp. 298-303, (2017)
18. Roschewski M, Phelan JD, Wilson WH., Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma, Cancer J, 26, 3, pp. 195-205, (2020)
19. Phan J, Mazloom A, Abboud M, Et al., Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy, Am J Clin Oncol, 34, 5, pp. 499-505, (2011)
20. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, Et al., Late cardiotoxicity after treatment for Hodgkin lymphoma, Blood, 109, 5, pp. 1878-1886, (2007)
21. Wahner-Roedler DL, Nelson DF, Croghan IT, Et al., Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience, Mayo Clin Proc, 78, 6, pp. 708-715, (2003)